<code id='E7D76E9D21'></code><style id='E7D76E9D21'></style>
    • <acronym id='E7D76E9D21'></acronym>
      <center id='E7D76E9D21'><center id='E7D76E9D21'><tfoot id='E7D76E9D21'></tfoot></center><abbr id='E7D76E9D21'><dir id='E7D76E9D21'><tfoot id='E7D76E9D21'></tfoot><noframes id='E7D76E9D21'>

    • <optgroup id='E7D76E9D21'><strike id='E7D76E9D21'><sup id='E7D76E9D21'></sup></strike><code id='E7D76E9D21'></code></optgroup>
        1. <b id='E7D76E9D21'><label id='E7D76E9D21'><select id='E7D76E9D21'><dt id='E7D76E9D21'><span id='E7D76E9D21'></span></dt></select></label></b><u id='E7D76E9D21'></u>
          <i id='E7D76E9D21'><strike id='E7D76E9D21'><tt id='E7D76E9D21'><pre id='E7D76E9D21'></pre></tt></strike></i>

          
          WSS
          The FDA building -- First Opinion coverage from STAT
          Adobe

          WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

          Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

          advertisement

          To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion